Y-mAbs Therapeutics, Inc. (YMAB)
Automate Your Wheel Strategy on YMAB
With Tiblio's Option Bot, you can configure your own wheel strategy including YMAB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol YMAB
- Rev/Share 1.9656
- Book/Share 1.9833
- PB 2.5714
- Debt/Equity 0.0067
- CurrentRatio 4.7712
- ROIC -0.3242
- MktCap 230946870.0
- FreeCF/Share -0.4273
- PFCF -11.9817
- PE -8.1477
- Debt/Assets 0.0054
- DivYield 0
- ROE -0.3059
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | YMAB | BofA Securities | Neutral | Underperform | -- | $3 | April 22, 2025 |
| Initiation | YMAB | Cantor Fitzgerald | -- | Overweight | -- | $20 | Aug. 16, 2024 |
News
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
Published: May 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of GD2-SADA in recurrent or refractory metastatic solid tumors known to express GD2 in a trial in progress poster at the Advances in Neuroblastoma Research Meeting (“ANR”) being held on May 25-28, 2025 in Washington, D.C.
Read More
Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Courtney Dugan - Vice President, Head of Investor Relations Michael Rossi - President and Chief Executive Officer Doug Gentilcore - DANYELZA Business Unit Head Peter Pfreundschuh - Chief Financial Officer Conference Call Participants Nicole Germino - Truist Securities Mike Ulz - Morgan Stanley Justin Walsh - Jones Trading Li Watsek - Cantor John Newman - Canaccord Genuity Jeff Jones - Oppenheimer Bill Maughan - Clear Street David Nierengarten - Wedbush Kemp Dolliver - Brookline Capital Markets Chiara Montironi - Van Lanschot Kempen …
Read More
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that naxitamab-gqgk (DANYELZA®) is recommended by the National Comprehensive Cancer Network® (“NCCN”) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a NCCN Category 2A treatment option for high-risk neuroblastoma.
Read More
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the first quarter 2025 before the market open on Tuesday, May 13, 2025.
Read More
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
Published: April 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of CD38-SADA in a poster at the 2025 American Association of Cancer Research (AACR) Annual Meeting being held on April 25-30, 2025 in Chicago, IL.
Read More
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
About Y-mAbs Therapeutics, Inc. (YMAB)
- IPO Date 2018-09-21
- Website https://www.ymabs.com
- Industry Biotechnology
- CEO Mr. Michael Rossi
- Employees 104